Their lead oncology therapeutic, SUPLEXA cells, is a non-engineered, tumor-agnostic cellular therapy platform that uses proprietary leukocyte activator cell lines to activate various subsets of peripheral blood mononuclear cells. Alloplex has developed SUPLEXA cells through an all-human in vitro assay, which models the intended ex vivo activation of patient PBMC. The company is exploring the combinatorial space of immunomodulators to develop an effective anti-tumor vaccine, applicable to all tumor types and particularly suited to combinations with checkpoint inhibitors. Alloplex is a private company currently supported by angel investment.